Insider Selling: BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells 19,770 Shares of Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) insider Alane Barnes sold 19,770 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $7.65, for a total value of $151,240.50. Following the completion of the sale, the insider directly owned 345,476 shares in the company, valued at approximately $2,642,891.40. The trade was a 5.41% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX traded up $0.69 during mid-day trading on Wednesday, hitting $7.85. 7,602,203 shares of the stock were exchanged, compared to its average volume of 4,026,871. The company has a market cap of $1.65 billion, a PE ratio of -157.00 and a beta of 0.91. BioCryst Pharmaceuticals, Inc. has a 52-week low of $6.00 and a 52-week high of $11.31. The firm has a 50-day moving average of $7.12 and a two-hundred day moving average of $8.38.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.01). The business had revenue of $159.40 million during the quarter, compared to the consensus estimate of $162.91 million. BioCryst Pharmaceuticals had a negative return on equity of 4.24% and a negative net margin of 1.46%.The company’s revenue for the quarter was up 36.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.07) EPS. On average, sell-side analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

Analyst Upgrades and Downgrades

BCRX has been the topic of a number of recent research reports. JMP Securities upped their price objective on BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the company a “market outperform” rating in a research report on Wednesday, October 15th. Barclays cut their target price on BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 4th. TD Cowen began coverage on BioCryst Pharmaceuticals in a research report on Wednesday, October 15th. They issued a “buy” rating and a $30.00 price target for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioCryst Pharmaceuticals in a research note on Tuesday. Finally, Needham & Company LLC reduced their target price on shares of BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, November 4th. Ten analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $19.33.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Allianz Asset Management GmbH raised its holdings in shares of BioCryst Pharmaceuticals by 9.6% in the first quarter. Allianz Asset Management GmbH now owns 13,700 shares of the biotechnology company’s stock valued at $103,000 after acquiring an additional 1,200 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH raised its holdings in shares of BioCryst Pharmaceuticals by 7.7% in the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 17,992 shares of the biotechnology company’s stock valued at $161,000 after purchasing an additional 1,288 shares in the last quarter. Royal Bank of Canada raised its holdings in shares of BioCryst Pharmaceuticals by 2.4% in the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock valued at $476,000 after purchasing an additional 1,458 shares in the last quarter. Captrust Financial Advisors lifted its position in shares of BioCryst Pharmaceuticals by 7.4% in the 2nd quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company’s stock worth $198,000 after purchasing an additional 1,527 shares during the period. Finally, Main Management ETF Advisors LLC boosted its stake in shares of BioCryst Pharmaceuticals by 1.7% during the second quarter. Main Management ETF Advisors LLC now owns 112,128 shares of the biotechnology company’s stock valued at $1,005,000 after purchasing an additional 1,824 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.